Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
Vaccine
; 29(4): 712-20, 2011 Jan 17.
Article
em En
| MEDLINE
| ID: mdl-21115057
ABSTRACT
An efficacious, low cost vaccine against typhoid fever, especially for young children, would make a major impact on disease burden in developing countries. The virulence capsular polysaccharide of Salmonella Typhi (Vi) coupled to recombinant mutant Pseudomonas aeruginosa exoprotein A (Vi-rEPA) has been shown to be highly efficacious. We investigated the use of carrier proteins included in infant vaccines, standardized the conjugation process and developed key assays required for routine lot release at production scale. Vi from a BSL1 organism, Citrobacter freundii, strain WR7011, was used as an alternative to Vi from S. Typhi. We showed that Vi conjugated to CRM(197), a non-toxic mutant of diphtheria toxin, widely used in commercial vaccines, was produced at high yield. Vi-CRM(197) proved immunogenic in animal studies, even without adjuvant. Thus, Vi-CRM(197) appears to be a suitable candidate for the development of a commercially viable, effective typhoid vaccine for developing countries.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Polissacarídeos Bacterianos
/
Proteínas de Bactérias
/
Febre Tifoide
/
Vacinas Antirrickéttsia
/
Adjuvantes Imunológicos
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article